About Hytanbio Tech
Founded in Hong Kong in 2026, Hytanbio Tech was established to coordinate global business development, customer communication and export projects. The company reports that its in-house commercial manufacturing base was established in 2014 in Shaoxing, Mainland China. For injectpens.com, the business focus is injection pen device platforms, B2B supply coordination and OEM/ODM development support. The site is intentionally written for brand owners, medical-device organizations, laboratories, distributors and cross-border procurement teams. It does not sell individual pens to patients and does not provide medical advice or instructions for administering medicine.
Engineering and production bridge
The organization reports an R&D center covering more than 4,000 square meters and an integrated path from concept evaluation through commercial manufacturing. In practical project terms, this means a brief can be examined for platform fit, design-for-manufacture, materials, interfaces, tooling, prototypes, inspection and production transfer without forcing the buyer to manage disconnected vendors. The depth of work varies by route. A standard wholesale platform requires configuration control and supply planning; a semi-custom project adds controlled branding or packaging; a full ODM program adds design inputs, development reviews, verification planning and new tooling. Deliverables, responsibilities and acceptance criteria are confirmed in the proposal and contract.
Who we serve
HYTANBIO works with professional organizations that need a clear device-development or sourcing pathway: skincare and life-science brands expanding into delivery systems, medical-device and pharmaceutical project teams, laboratories, beauty and wellness institutions operating within applicable rules, and cross-border distributors. The commercial conversation begins with intended use, target market, primary container, dose concept, annual forecast, branding scope and evidence expectations. If those inputs show that a request is outside the available platform or compliance boundary, the project is not presented as ready merely to win an order. That discipline protects the buyer, the supplier and the downstream program.
Quality and compliance boundary
The company reports an ISO 9001:2015 quality-management certification. Any buyer relying on that fact should request the certificate and verify the entity, site, scope, issuing body and validity. Device- or market-specific claims such as CE marking, FDA status, GMP scope or ISO 13485 require separate evidence and are not inferred from a company profile, facility photograph or badge. Final market access depends on the product configuration, medicinal-product relationship, legal manufacturer and destination-market requirements. HYTANBIO supports the project-specific documentation and coordination defined in writing.